Epilepsy Drugs Market in Europe to Grow at a CAGR of 3.22% 2014-2019
The epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019. Reformulated medicines usually have better tolerability, reduced dosing regimen, and decreased developmental costs than original drugs. Few vendors are focusing on developing such drugs instead of manufacturing new drugs. For instance, Neurontin by Pfizer, Keppra by UCB, and Trobalt by GlaxoSmithKline are film-coated tablets that were recently launched in the market.
View full press release